Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Acorda Therapeutics (NQ: ACOR )

0.6000 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Acorda Therapeutics

< Previous 1 2 Next >
Acorda Therapeutics CEO Ron Cohen, M.D., to Hold Virtual Company Presentation and Q&A
From Acorda Therapeutics
Via Business Wire
Acorda Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
From Acorda Therapeutics
Via Business Wire
ESTEVE Launches INBRIJA® in Spain
From Acorda Therapeutics
Via Business Wire
Acorda Fourth Quarter/Year End 2022 Update: Webcast/Conference Call Scheduled for March 9, 2023
From Acorda Therapeutics
Via Business Wire
Acorda Therapeutics Receives Nasdaq Extension to Meet Minimum Bid Price Requirement
From Acorda Therapeutics
Via Business Wire
Acorda Therapeutics to Present at Sequire Biotechnology Conference
From Acorda Therapeutics
Via Business Wire
Acorda Therapeutics Announces New Agreement with Catalent for Long-Term Global Supply of INBRIJA®
From Acorda Therapeutics
Via Business Wire
Acorda Therapeutics Announces Revised Long-Term Financial Guidance
From Acorda Therapeutics
Via Business Wire
Acorda Therapeutics Receives Nasdaq Listing Determination Letter and Plans to Request a Hearing
From Acorda Therapeutics
Via Business Wire
Acorda Therapeutics Makes December 2022 $6.2 Million Interest Payment on Secured Debt in Cash
From Acorda Therapeutics
Via Business Wire
Acorda Therapeutics Announces Passage of Reverse Stock Split Proposal at its Special Meeting of Stockholders
From Acorda Therapeutics
Via Business Wire
Acorda Therapeutics Announces Adjournment of Special Meeting of Stockholders
From Acorda Therapeutics
Via Business Wire
Acorda Therapeutics Reports Third Quarter 2022 Financial Results
From Acorda Therapeutics
Via Business Wire
Acorda Therapeutics Provides Long-Term Business Plan and Financial Guidance
From Acorda Therapeutics
Via Business Wire
Acorda Third Quarter 2022 Update: Webcast/Conference Call Scheduled for November 1, 2022
From Acorda Therapeutics
Via Business Wire
Acorda Shareholders Invited to Virtual Q&A with CEO Ron Cohen, M.D.
From Acorda Therapeutics
Via Business Wire
ISS, Glass Lewis, and Egan-Jones Recommend that Acorda Stockholders Vote FOR the Proposal to Implement a Reverse Stock Split
From Acorda Therapeutics
Via Business Wire
Acorda Therapeutics Will Not Use Shares for December 2022 $6.2 Million Interest Payment on Secured Debt
From Acorda Therapeutics
Via Business Wire
Acorda Therapeutics Announces $16.5M Award and Royalty/Supply Relief in AMPYRA® Arbitration Case
From Acorda Therapeutics
Via Business Wire
Acorda Therapeutics Withdraws Proposal to Increase Authorized Shares from Special Meeting of Stockholders
From Acorda Therapeutics
Via Business Wire
Acorda Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference
From Acorda Therapeutics, Inc.
Via Business Wire
Acorda Therapeutics Enters into License Agreement with Asieris Pharmaceuticals
From Acorda Therapeutics, Inc.
Via Business Wire
Acorda Therapeutics Announces Resignation of Chief Operating Officer
From Acorda Therapeutics, Inc.
Via Business Wire
Acorda Therapeutics Reports Second Quarter 2022 Financial Results
From Acorda Therapeutics, Inc.
Via Business Wire
Acorda Second Quarter 2022 Update: Webcast/Conference Call Scheduled for August 4, 2022
From Acorda Therapeutics, Inc.
Via Business Wire
Esteve Launches INBRIJA® in Germany
From Acorda Therapeutics, Inc.
Via Business Wire
Acorda Therapeutics Reports First Quarter 2022 Financial Results
From Acorda Therapeutics, Inc.
Via Business Wire
Acorda Therapeutics and Biopas Laboratories Announce Agreement to Commercialize INBRIJA® in Latin America
From Acorda Therapeutics, Inc.
Via Business Wire
Acorda First Quarter 2022 Update: Webcast/Conference Call Scheduled for May 11, 2022
From Acorda Therapeutics, Inc.
Via Business Wire
Acorda Fourth Quarter/Year End 2021 Update: Webcast/Conference Call Scheduled for March 9, 2022
From Acorda Therapeutics, Inc.
Via Business Wire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.